Publications of Andrée RORIVE
Bookmark and Share    
Full Text
See detailGranulomatous reactions from tattoos following BRAF inhibitor therapy
GIET, Gabrielle ULiege; LEBAS, Eve ULiege; RORIVE, Andrée ULiege et al

in Case Reports in Dermatology (2019), 11

Detailed reference viewed: 36 (4 ULiège)
Full Text
See detailPatient avec un carcinome spinocellulaire cutané localement avancé et métastatique traité par Cemiplimab
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue Médicale de Liège (2019), (74), 1-5

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de ... [more ▼]

Le traitement du carcinome spinocellulaire cutané (cSCC) localement avancé et/ou métastasique repose essentiellement sur la chirurgie et, éventuellement, une radiothérapie de la zone chirurgicale et de l’aire ganglionnaire afférente. Malheureusement, certains cas ne sont plus opérables ou accessibles à la radiothérapie et un traitement systémique est alors indiqué. Les chimiothérapies sont peu efficaces et potentiellement toxiques. Une étude récente évaluant l’efficacité et la tolérance du cemiplimab, un antagoniste PD1, dans les cSCC localement avancés et métastasiques démontre une réponse objective confirmée de 49 % et de 47 %, respectivement, avec un maintien de la réponse d’au moins 6 mois de 63 % et de 60 %, respectivement. Nous présentons le cas d’un patient avec un cSCC localement avancé au niveau du front, avec effraction osseuse et adénopathies cervicales, ayant eu de multiples chirurgies et radiothérapies. Il a présenté une réponse partielle au cemiplimab avec un profil de tolérance satisfaisant. [less ▲]

Detailed reference viewed: 56 (7 ULiège)
Full Text
See detailCarcinome spinocellulaire cutané localement avancé et métastatique traité par cemiplimab.
Vanhakendover, Louise ULiege; LEBAS, Eve ULiege; Libon, Florence ULiege et al

in Revue medicale de Liege (2019), 74(7-8), 436-440

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes ... [more ▼]

The treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) essentially relies on surgery and eventually radiotherapy of the treated site and afferent lymph nodes. Unfortunately, some cases are no candidates for surgery or radiotherapy and a systemic treatment may be indicated. Chemotherapies are only partially efficacious and associated with potential toxicities. A recent study evaluating the efficacy and tolerance of cemiplimab, a PD1 antagonist for locally advanced and metastatic cSCC demonstrated an objective response rate of 49 % and 47 % for locally advanced and metastatic cSCC, while maintaining a response of at least 6 months of 63 % and 60 %, respectively. We present a clinical case of a patient with a locally advanced cSCC of the forehead with bone resorption and cervical lymphadenopathies. After failure of multiple surgical interventions and radiotherapies, he responded partially to cemiplimab immunotherapy with a good safety profile. [less ▲]

Detailed reference viewed: 143 (15 ULiège)
Full Text
See detailCancer du sein: intérêt du bilan d’extension par imagerie lors du diagnostic initial et du suivi les trois premières années après le diagnostic
SCHROEDER, Hélène ULiege; Hanocq, Florence ULiege; COLLIGNON, Joëlle ULiege et al

in Revue Médicale de Liège (2015), 70(3), 140-147

In our region, repeated tumor staging by radiological procedures aiming to detect relapses and/or metastases from breast cancer is frequently performed. However, these procedures are not recommended by ... [more ▼]

In our region, repeated tumor staging by radiological procedures aiming to detect relapses and/or metastases from breast cancer is frequently performed. However, these procedures are not recommended by current international guidelines. We retrospectively analyzed the charts from 818 patients with a new diagnosis of breast cancer seen at CHU Liege between 2005 and 2009. We assessed the role of staging procedures at initial diagnosis and during follow-up the first 3 years after the diagnosis of breast cancer. Twenty-six patients presented with metastatic disease at diagnosis and 55 patients developed loco-regional relapses or metastases during follow-up. For asymptomatic patients, imaging procedures only detected tumor metastases or relapse without elevated tumor markers in 9 patients at initial diagnosis and 10 patients during follow-up. The diagnosis of an asymptomatic relapse and/or metastases had no positive impact on progression-free or overall survival. The anatomic extension identified patients at high risk for presenting distant metastases already at the time of initial diagnosis and the biological aggressiveness evaluated by Ki-67 was an important prognostic factor for early relapse. In view of these results, we do not recommend staging and searching for metastatic disease in asymptomatic patients presenting early stage breast cancer with low expression of the Ki-67 at the time of initial diagnosis. We also do not recommend repeated staging and searching for metastases by imaging in asymptomatic patients during routine follow-up. Staging should only be performed if a relapse is suspected during follow-up. [less ▲]

Detailed reference viewed: 192 (21 ULiège)
Full Text
See detailCancer du sein : de la thérapie ciblée à la médecine personnalisée
JERUSALEM, Guy ULiege; COLLIGNON, Joëlle ULiege; Josse, Claire ULiege et al

in Revue Médicale de Liège (2015), 70(5-6), 269-276

Dans cet article, les auteurs passent en revue les grands principes de prise en charge du traitement systémique du cancer du sein et posent la question suivante : jusqu'où réellement aujourd'hui ce ... [more ▼]

Dans cet article, les auteurs passent en revue les grands principes de prise en charge du traitement systémique du cancer du sein et posent la question suivante : jusqu'où réellement aujourd'hui ce traitement est-il individualisé ? Les nouvelles technologies permettent une analyse détaillée des anomalies génomiques au niveau des cellules cancéreuses. Malheureusement, nous n'avons pas encore compris comment utiliser au mieux ces données au bénéfice du patient. La majorité des modifications du génome sont des évènements relativement rares compliquant le développement de nouveaux médicaments dans le cadre d'une médecine de précision. De plus, les tumeurs présentent une grande hétérogénéité temporelle et spatiale dont il faudra tenir compte lors de ce développement. Une collaboration internationale intensive est en cours pour tenter de confirmer que la médecine de précision permet d'optimiser les résultats du traitement systémique dans le cancer du sein. [less ▲]

Detailed reference viewed: 495 (30 ULiège)
Full Text
See detailBIOPSIE DES LESIONS SUSPECTES CHEZ LES PATIENTS AYANT PRESENTE UN CANCER DU SEIN.
COLIN, Paul-Emile ULiege; SCHROEDER, Hélène ULiege; GONNE, Elodie ULiege et al

in Revue Médicale de Liège (2015), 70(11), 563-8

Discordances between hormone receptors and HER2 status in primary and metastatic breast cancer have been reported by several studies. In this context, systematic biopsies could be clinically relevant in ... [more ▼]

Discordances between hormone receptors and HER2 status in primary and metastatic breast cancer have been reported by several studies. In this context, systematic biopsies could be clinically relevant in breast cancer to confirm the biological characteristics of a suspicious lesion. In this article, illustrated by 2 case reports and based on a recent review on this topic, we discuss the clinical significance of receptor discordances and possible diagnosis of a secondary primary tumor. The role of these biopsies for the identification of new therapeutic targets is also envisaged as well as underlying mechanisms for receptors' modification like tumoral heterogeneity, clonal selection and technical artifacts. [less ▲]

Detailed reference viewed: 118 (6 ULiège)
Full Text
See detailUse of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
Jerusalem, Guy ULiege; RORIVE, Andrée ULiege; COLLIGNON, Joëlle ULiege

in Breast Cancer (2014), 6

Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents ... [more ▼]

Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-positive, HER2-negative advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus). This study showed a statistically significant and clinically meaningful improvement in median progression-free survival. Results concerning the impact on overall survival are expected in the near future. This clinically oriented review focuses on the use of mTOR inhibitors in breast cancer. Results reported with first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed. The current and potential role of mTOR inhibitors is reported according to breast cancer subtype (estrogen receptor-positive HER2-negative, triple-negative, and HER2-positive ER-positive/negative disease). Everolimus is currently being evaluated in the adjuvant setting in high-risk estrogen receptor-positive, HER2-negative early breast cancer. Continuing mTOR inhibition or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under evaluation. Potential biomarkers to select patients showing a more pronounced benefit are reviewed, but we are not currently using these biomarkers in routine practice. Subgroup analysis of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible to select patients not benefiting from addition of everolimus to exemestane. Side effects and impact on quality of life are other important issues discussed in this review. Second-generation mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being evaluated in clinical trials. [less ▲]

Detailed reference viewed: 72 (8 ULiège)
Full Text
See detailAccelerated partial breast irradiation: state of the art
COUCKE, Philippe ULiege; JANSEN, Nicolas ULiege; JANVARY, Zsolt Levente ULiege et al

in Belgian Journal of Medical Oncology (2011), 5(1), 3-7

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for ... [more ▼]

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for less exposure of healthy tissue to higher radiation doses. However, evidence <br />issued from randomized trials is limited. European and American experts call our attention <br />to the potential dangers of widespread implementation of these techniques without any <br />long-term data on outcome and ask for complete information of patients on the potential <br />hazards and risks if accelerated partial breast irradiation is used instead of whole breast <br />irradiation. [less ▲]

Detailed reference viewed: 80 (12 ULiège)
Full Text
See detailLe cancer du sein chez la femme jeune
ANDRE, Chantal ULiege; COLLIGNON, Joëlle ULiege; RORIVE, Andrée ULiege et al

in Revue Médicale de Liège (2011), 66(5-6), 397-399

Detailed reference viewed: 252 (31 ULiège)
Full Text
See detail18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers
Withofs, Nadia ULiege; Grayet, Benjamin ULiege; Tancredi, Tino ULiege et al

in Nuclear Medicine Communications (2011), 32(3), 168-176

Detailed reference viewed: 128 (30 ULiège)
Full Text
See detailLe cancer du sein "triple négatif"
Freres, Pierre; Collignon, Joëlle ULiege; Gennigens, Christine ULiege et al

in Revue Médicale de Liège (2010), 65(3), 120-126

Le cancer du sein touche une femme sur huit dans les pays occidentaux. Son incidence a considérablement augmenté au cours de ces deux dernières décennies mais, en même temps, le niveau de mortalité ... [more ▼]

Le cancer du sein touche une femme sur huit dans les pays occidentaux. Son incidence a considérablement augmenté au cours de ces deux dernières décennies mais, en même temps, le niveau de mortalité spécifique est resté stable et a même diminué en Europe et aux Etats-Unis, notamment, grâce à l’apport de nouvelles armes thérapeutiques, aux changements dans l’utilisation du traitement hormonal substitutif à la ménopause et à un diagnostic plus précoce. Malgré cela, le cancer du sein reste la première cause de décès par cancer chez la femme de moins de 65 ans. Le cancer du sein «triple négatif», un sous-type représentant environ 10 % des cancers du sein, est caractérisé par l’absence de récepteurs hormonaux aux oestrogènes et à la progestérone et l’absence d’expression du facteur de croissance HER-2 en étude d’immunohistochimie. Ce type de cancer du sein est associé à un profil clinique défavorable avec un haut risque de rechute métastatique précoce. De plus, le cancer du sein «triple négatif» ne présente aucune cible thérapeutique propre et son pronostic est donc particulièrement mauvais. La définition de facteurs prédictifs de la réponse tumorale aux différents traitements et l’apport des thérapies ciblées sont deux pistes susceptibles d’améliorer la prise en charge et la survie des patients atteints par ce type de cancer extrêmement agressif. [less ▲]

Detailed reference viewed: 1043 (41 ULiège)
Full Text
See detailPourquoi les traitements de radiothérapie adjuvante pour cancer du sein ne comptent-ils plus autant de séances ?
Coucke, Philippe ULiege; Jansen, Nicolas ULiege; Collignon, Joëlle ULiege et al

in Revue Médicale de Liège (2010), 65(1), 10-14

La radiothérapie adjuvante postopératoire pour cancer du sein compte habituellement vingt-cinq séances de radiothérapie auxquelles on ajoute une surimpression centrée sur le lit tumoral. Dans le contexte ... [more ▼]

La radiothérapie adjuvante postopératoire pour cancer du sein compte habituellement vingt-cinq séances de radiothérapie auxquelles on ajoute une surimpression centrée sur le lit tumoral. Dans le contexte d’une augmentation progressive et continue de la charge de travail et afin de réduire les contraintes humaines et techniques, une radiothérapie plus courte est aujourd’hui utilisée. Ces schémas hypo-fractionnés sont validés par des essais randomisés et publiés. Sur la base de ces publications, un nouvel arbre décisionnel a été établi qui permet d’obtenir des résultats équivalents en contrôle local tout en gardant un taux de complications comparable, voire même inférieur au schéma classique [less ▲]

Detailed reference viewed: 159 (12 ULiège)
Full Text
See detailL'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein
Bleret, Valerie ULiege; Collignon, Joëlle ULiege; Coucke, Philippe ULiege et al

in Revue Médicale de Liège (2010), 65(5-6), 405-408

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité ... [more ▼]

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité démontrée de l'hormonothérapie, la compliance constitue un défi majeur et un problème multidimensionnel. Une meilleure compréhension des raisons de cette non-compliance aiderait à mieux identifier les patientes à risque et à développer des interventions capables d'améliorer l'adhésion à l'hormonothérapie adjuvante.C'est dans ce but que nous avons entrepris une revue de la littérature des six dernières années (Pub Med 2003-2006). [less ▲]

Detailed reference viewed: 336 (35 ULiège)
Full Text
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULiege; Gennigens, Christine ULiege; Rorive, Andrée ULiege et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 594 (45 ULiège)
Full Text
See detailAnticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites.
Gennigens, Christine ULiege; Collignon, Joëlle ULiege; Jerusalem, Guy ULiege et al

in Revue Médicale de Liège (2009), 64(5-6), 264-7

For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation ... [more ▼]

For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation, growth and metastasis have led to the identification of specific pathways playing a role in the pathophysiology of cancer. New drugs specifically developed to control these targets are collectively named "targeted therapies". Two types of targeted therapies are available: kinase (mainly tyrosine kinase) inhibitors (suffix -nib) are small molecules binding directly to the intracellular kinase domain and acting as competitive inhibitor of ATP binding and monoclonal antibodies (suffix -mab) directed towards specific cell surface receptors or their ligands to prevent receptor activation. This paper will only review monoclonal antibodies (mabs). Thirty years after their discovery mAbs have become efficient therapeutic tools. Progress in molecular engineering as well as improved knowledge of cell signalling pathways together with a better selection of the targets turned them into valuable treatments. Several mAbs are currently licensed for the treatment of hematological or solid malignancies and many others are expected in the near future. [less ▲]

Detailed reference viewed: 205 (7 ULiège)
Full Text
See detailLe cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide.
Mievis, Carole ULiege; Jansen, Nicolas ULiege; Schleich, FLorence ULiege et al

in Revue Médicale de Liège (2009), 64(4), 179-81

Radiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic ... [more ▼]

Radiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic agents such as gemcitabine, taxanes, anthracyclines. We report the case of a 50-year-old man with metastatic prostate cancer who developed two consecutive radiation recall dermatitis episodes triggered by oral cyclophosphamide. They occurred 4 to 5 weeks after palliative radiotherapy on bone metastasis. Spontaneous resolution was observed within 6 weeks after discontinuation of cyclophosphamide and with local supportive care. To our knowledge this is the first reported case of radiation recall dermatitis after oral cyclophosphamide. [less ▲]

Detailed reference viewed: 323 (12 ULiège)
Full Text
See detailComment j'explore... une metastase cutanee. Qui es-tu, d'ou viens-tu?
Quatresooz, Pascale ULiege; Pierard, Claudine ULiege; Rorive, Andrée ULiege et al

in Revue Médicale de Liège (2008), 63(9), 559-63

Cutaneous metastases may accompany up to 3 to 10% of all malignancies. They are usually identified after diagnosing the primary neoplasm. However, their disclosure can be synchronous, or the metastasis ... [more ▼]

Cutaneous metastases may accompany up to 3 to 10% of all malignancies. They are usually identified after diagnosing the primary neoplasm. However, their disclosure can be synchronous, or the metastasis may be the initial finding qualified as "precocious". The identification of the primary neoplasm sometimes proves to be difficult. Gender of the patient, the aspect and distribution of the metastases, as well as the histological and immunohistological examinations help establishing the diagnosis. The prognosis of the metastatic disease is often poor. [less ▲]

Detailed reference viewed: 120 (3 ULiège)
Full Text
See detailLe melanome cutane: innovations conceptuelles et therapeutiques, fruit de la recherche translationnelle.
Pierard, Gérald ULiege; Quatresooz, Pascale ULiege; Rorive, Andrée ULiege et al

in Revue Médicale de Liège (2008), 63(10), 579-84

The scientific information about melanoma is on the rise. It has a direct impact on the diagnostic acuteness and on the therapeutic management. The most recent aspects of the utmost importance are ... [more ▼]

The scientific information about melanoma is on the rise. It has a direct impact on the diagnostic acuteness and on the therapeutic management. The most recent aspects of the utmost importance are presented. The concept of the duality between fast-growing (high malignancy) and slow-growing (reduced malignancy) melanoma is stressed. A new international multicentric approach using adjuvant therapy for stage III melanomas involves the clinical oncology department of the CHU of Liege. It concerns a targeted immunotherapy directed to the Mage A3 protein. [less ▲]

Detailed reference viewed: 195 (9 ULiège)
Full Text
See detailActualites therapeutiques en oncologie: l'essor des therapeutiques ciblees
Gennigens, Christine ULiege; Sautois, Brieuc ULiege; Rorive, Andrée ULiege et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 391-8

Over the last decades, significant advances were make in basic research as concerns the malignant transformation of normal cells. As a result, new targets for treatment were identified. "Targeted ... [more ▼]

Over the last decades, significant advances were make in basic research as concerns the malignant transformation of normal cells. As a result, new targets for treatment were identified. "Targeted therapies" indicates that treatments are directed against specific molecular targets that play a major role in the activation of cell division and in the growth and dissemination of tumors. In particular, targeted therapies were developed against epithelial growth factor receptors and angiogenesis. We can expect specifise therapies against many other targets in the near future. Several drugs have obtained a marketing license. Predictive factors for tumor response and long term outcome should be developed for a better selection of the patient population who will benefit from these treatments. New imaging techniques are under development in order to assess the molecular response to these new approaches. [less ▲]

Detailed reference viewed: 300 (12 ULiège)
Full Text
See detailActualités thérapeutiques en oncologie sénologique: place actuelle et perspectives des traitements cibles
Jerusalem, Guy ULiege; Rorive, Andrée ULiege; Gennigens, Christine ULiege et al

in Revue Médicale de Liège (2007), 62 Spec No

The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and ... [more ▼]

The introduction of targeted therapies has largely modified the treatment strategies in oncology. Two targets are currently used for defining the systemic treatment of breast cancer: hormone receptors and HER2 overexpression. Trastuzumab, a monoclonal antibody, is the only registered antiHER2 treatment in Belgium. The association of trastuzumab with chemotherapy is now the recommended adjuvant treatment for early breast cancer overexpressing HER2. Other antiHER2 medications are available and some will probably be registered soon. Angiogenesis is another potential target for improving the treatment results. The CHU Liege, as a reference center for the systemic treatment of solid tumors, participates in many international trials in order to validate these new approaches. The highest quality of care is required to be in compliance with the conduct of these clinical trials. Another benefit for the patient is the easy access to last generation medical treatments, generally not accessible in our health care system in Belgium outside of clinical trials. [less ▲]

Detailed reference viewed: 161 (10 ULiège)